PMID- 2107761
OWN - NLM
STAT- MEDLINE
DCOM- 19900423
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 258
IP  - 3 Pt 2
DP  - 1990 Mar
TI  - Chemotactic peptide FMLP contracts human coronary arteries via cyclooxygenase 
      products.
PG  - H848-53
AB  - The chemotactic peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) is a 
      constrictor of bronchial smooth muscle. Recently it has also been shown to 
      contract rabbit coronary arteries by an unknown mechanism. This prompted us to 
      investigate whether the chemotactic peptide has an effect on the tone of human 
      coronary arteries obtained during heart transplantation. FMLP was found to be a 
      potent and efficacious myotropic agent on strips of human coronary artery. 
      Contractions were generally transient and subject to tachyphylaxis. The 
      FMLP-induced vasoconstriction was not dependent on the presence of endothelial 
      cells. The response was unaffected by the histamine H1-antagonist diphenhydramine 
      or the antagonist of peptido-leukotrienes FPL 55712. However, the contractions 
      were completely abolished in the presence of the fatty acid cyclooxygenase 
      inhibitors aspirin or indomethacin. Stimulation of rings of human coronary artery 
      with FMLP resulted in a marked production of prostaglandin (PG)F2 alpha, a 
      smaller production of PGD2, and a slight increase in thromboxane B2. All these 
      prostanoids constricted the artery, but the stable thromboxane mimetic U44069 was 
      100 times more potent than PGF2 alpha or PGD2. These data indicate that FMLP 
      activates cells of unknown identity in the adventitia or media of human coronary 
      arteries to produce a mixture of vasoconstrictor cyclooxygenase products. These 
      compounds are likely to mediate the myotropic effect of FMLP on this artery. The 
      mechanism may participate in the pathogenesis of some forms of coronary 
      vasospasm.
FAU - Bode, S M
AU  - Bode SM
AD  - Department of Clinical Pharmacology, Hannover Medical School, Federal Republic of 
      Germany.
FAU - Kuhn, M
AU  - Kuhn M
FAU - Forstermann, U
AU  - Forstermann U
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 0 (Chemotactic Factors)
RN  - 0 (Prostaglandins)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Animals
MH  - Aorta/drug effects
MH  - Biomechanical Phenomena
MH  - Chemotactic Factors/pharmacology
MH  - Coronary Vessels/*drug effects/metabolism
MH  - Humans
MH  - Middle Aged
MH  - N-Formylmethionine Leucyl-Phenylalanine/*pharmacology
MH  - Prostaglandin-Endoperoxide Synthases/*metabolism
MH  - Prostaglandins/biosynthesis/pharmacology
MH  - Rabbits
MH  - Vasoconstriction/*physiology
EDAT- 1990/03/01 00:00
MHDA- 1990/03/01 00:01
CRDT- 1990/03/01 00:00
PHST- 1990/03/01 00:00 [pubmed]
PHST- 1990/03/01 00:01 [medline]
PHST- 1990/03/01 00:00 [entrez]
AID - 10.1152/ajpheart.1990.258.3.H848 [doi]
PST - ppublish
SO  - Am J Physiol. 1990 Mar;258(3 Pt 2):H848-53. doi: 
      10.1152/ajpheart.1990.258.3.H848.